The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
While privately insured people are eligible to have the cost of coronavirus testing covered 100% by their health plan, that doesn't mean that insured patients won’t be asked to pay up front for the cost of testing or that they can easily be reimbursed.
This blog is an overview of the outstanding questions related to the $100 billion for hospitals and other providers in the CARES Act and whether there will be meaningful protections for the uninsured and people with private coverage who could face surprise bills.
This 10-question quiz tests your knowledge about the coronavirus and COVID-19, including issues around symptoms, testing, number of cases and deaths, and cost sharing for treatment.
This summarizes key provisions of the No Surprises Act, enacted in December 2020 to address the problem of unexpected medical bills, and issues that could arise during implementation ahead of its Jan. 1, 2022 effective date.
This analysis examines list prices for COVID-19 testing at the largest hospitals in every state and finds they range widely from $20 to $850. Federal law now requires private insurers to cover COVID-19 tests at no cost to the patient and provides funding for people without health insurance.
This data note explores findings from on an 8-day online search for at home COVID-19 tests at major retailers. The findings are described against the backdrop of the Biden Administration policy requiring plans to cover the cost of these tests. We find that these tests remain hard to find and that this limited availability could negatively affect the success of the reimbursement strategy.
An updated issue brief estimates the number of enrollees in individual and fully-insured group market plans that have waived cost-sharing – out-of-pocket costs including coinsurance, copayments, and deductibles – for COVID-19 treatment. The analysis also estimates the number of enrollees whose insurer is offering various forms of premium payment relief.
About 88% – nearly nine in ten – enrollees in the individual and fully-insured group markets are covered by plans that have taken action to limit out-of-pocket costs for patients undergoing treatment for COVID-19 since the start of the pandemic. However, after accounting for waivers that have already expired (20%) or are scheduled to expire by the end of September (16%), just over half of enrollees in these plans will still be eligible for waived cost-sharing in October and beyond.
This issue brief compares President Trump and Democratic nominee Joe Biden on their records, actions and proposals related to the COVID-19 pandemic. It includes a general overview of their respective approaches, followed by a detailed side-by-side.
Few issues are likely to matter as much to voters in November’s presidential election as President Trump’s response to the COVID-19 pandemic and resulting economic crisis, which have left almost 200,000 Americans dead and prompted job layoffs and furloughs affecting tens of millions of Americans.
© 2026 KFF